Reversal of lung fibrosis in mouse model suggests a novel therapeutic target for pulmonary fibrosis

Researchers have reversed lung fibrosis in a mouse model of idiopathic pulmonary fibrosis. Mice were given bleomycin for 12 days to establish lung fibrosis, and then treated daily until 21 days with ABT-199, whose medical form is known as Venetoclax, a medication approved by the United States Food and Drug Administration for use in several forms of leukemia. Control bleomycin mice had lung fibrosis with widespread collagen deposition. The bleomycin mice that received ABT-199 had normal lung architecture at 21 days and no collagen deposition. These results suggest a novel therapeutic target to reverse fibrotic remodeling in the lungs.

from Top Health News -- ScienceDaily https://ift.tt/2UOr1Nu
via IFTTT